UroGen Pharma Ltd’s recently made public that its Chief Medical Officer Schoenberg Mark unloaded Company’s shares for reported $50698.0 on Jan 31 ’25. In the deal valued at $11.14 per share,4,551 shares were sold. As a result of this transaction, Schoenberg Mark now holds 145,666 shares worth roughly $1.55 million.
Then, Smith Jason Drew sold 7,379 shares, generating $82,202 in total proceeds. Upon selling the shares at $11.14, the General Counsel now owns 26,468 shares.
Before that, Schoenberg Mark sold 859 shares. UroGen Pharma Ltd shares valued at $11,236 were divested by the Chief Medical Officer at a price of $13.08 per share. As a result of the transaction, Schoenberg Mark now holds 145,091 shares, worth roughly $1.54 million.
A number of analysts have revised their coverage, including Guggenheim’s analysts, who began to cover the stock in late August with a ‘”a Buy”‘ rating. Jefferies also remained covering URGN and has decreased its forecast on February 08, 2023 with a “Hold” recommendation from previously “Buy” rating. Berenberg started covering the stock on April 27, 2022. It rated URGN as “a Buy”.
Price Performance Review of URGN
On Tuesday, UroGen Pharma Ltd [NASDAQ:URGN] saw its stock fall -3.89% to $10.63. Over the last five days, the stock has lost -6.75%. UroGen Pharma Ltd shares have fallen nearly -0.19% since the year began. Nevertheless, the stocks have fallen -29.13% over the past one year. While a 52-week high of $20.70 was reached on 03/24/25, a 52-week low of $9.03 was recorded on 02/28/25. SMA at 50 days reached $10.68, while 200 days put it at $12.78.
Levels Of Support And Resistance For URGN Stock
The 24-hour chart illustrates a support level at 10.35, which if violated will result in even more drops to 10.08. On the upside, there is a resistance level at 11.11. A further resistance level may holdings at 11.60. The Relative Strength Index (RSI) on the 14-day chart is 44.41, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.46, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 96.13%. Stochastics %K at 30.60% indicates the stock is a holding.
How much short interest is there in UroGen Pharma Ltd?
A steep rise in short interest was recorded in UroGen Pharma Ltd stocks on 2025-03-14, dropping by 42054.0 shares to a total of 6.15 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 6.19 million shares. There was a decline of -0.68%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on April 16, 2020 when H.C. Wainwright resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $57.
